Menu Search
Equities

Bionano Genomics Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
0A4K:LSE

Bionano Genomics Inc

Actions
  • Price (USD)--
  • Today's Change--
  • Shares traded--
  • 1 Year change--
  • Beta1.6838
Data delayed at least 20 minutes, as of Jan 31 2025.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Bionano Genomics, Inc. is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company offers optical genome mapping (OGM) solutions for applications across basic, translational and clinical research. It also offers a platform-agnostic software solution, which integrates sequencing and microarray data designed to provide analysis, visualization, interpretation and reporting of copy number variants, single-nucleotide variants, and absence of heterozygosity across the genome in one consolidated view. The Company additionally offers nucleic acid extraction and purification solutions using proprietary isotachophoresis (ITP) technology. The Company markets and sells OGM systems, including the Saphyr system, which delivers OGM data to enable ultra-sensitive and ultra-specific detection of all classes of structural variation (SV).

  • Revenue in USD (TTM)28.72m
  • Net income in USD-38.59m
  • Incorporated2003
  • Employees98.00
  • Location
    Bionano Genomics Inc9540 Towne Centre Drive, Suite 100SAN DIEGO 92121United StatesUSA
  • Phone+1 (858) 888-7600
  • Fax+1 (858) 888-7601
  • Websitehttps://bionano.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.